Merck that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg for the treatment of HIV-1 infection.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck provides update on Phase 3 MOVe-AHEAD trial evaluating LAGEVRIO
- Merck: FDA accepts for priority review sNDAs for PREVYMIS
- Merck announces sale of campus in Kenilworth, N.J.
- Merck’s Keytruda with chemotherapy shows improvements in Phase 3 trial
- AstraZeneca, Merck present final results from Phase III PROpel trial